ACBM · Acro Biomedical Co., Ltd.
$0.03
At close · Jun 16
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date of the financial statements being issued. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025, financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.56M
Shares
60.04M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.03
Open$0.03
Day$0.03–0.03
Available close range$0.02–0.03
Avg vol 30d2K
Short int4 · 0.0% float
Short vol85%
DataJan 2020–Jun 2026
Filing10-Q · Aug 14
The closing range uses available history since Dec 29, 2025; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−99%
below
Price vs 50-day avg
−99%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
100%
near high
Momentum
relative strength
1-month return
−99%
trailing
6-month return
−99%
trailing
YTD return
+17%
this year
Relative strength
−109%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
3102%
annualized · 1-yr
Max drawdown
−100%
past year
ATR
1270.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−99%
Bearish
Price vs 50-day avg
−99%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
100%
Bullish
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its available closing range
Range low $0
Now $0 · 100%
Range high $0
vs 200-day avg -99%
vs 50-day avg -99%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACBM
this stock
Acro Biomedical Co., Ltd.
|
$1.56M | +17.1% | +74.1% | — | 0.0% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
CCXI
Churchill Capital Corp XI
|
$778.13M | — | — | — | 6.0% |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$645.92M | +2.4% | — | — | 0.2% |
|
EVAC
EQV Ventures Acquisition Corp. II
|
$602.01M | +2.7% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACBM | +17.1% | -99.2% | -99.5% | +0.0% | +17.1% |
| SPY | +1.8% | +1.6% | +9.6% | -0.8% | +10.0% |
| vs SPY | +15.3% | -100.7% | -109.0% | +0.8% | +7.1% |